Combination of aspirin with telmisartan suppresses the augmented TGFβ/smad signaling during the development of streptozotocin-induced type I diabetic nephropathy

Chemico-Biological Interactions

Volumn 185, Issue 2, 2010, Pages 137-142

  Mulay, Shrikant Ramesh ^a   Gaikwad, Anil Bhanudas ^a   Tikoo, Kulbhushan ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Aspirin; Diabetes; Inflammation; Nephropathy; Telmisartan

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; SMAD PROTEIN; STREPTOZOCIN; TELMISARTAN; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG MECHANISM; DRUG RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NONHUMAN; RAT; SIGNAL TRANSDUCTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BENZIMIDAZOLES; BENZOATES; CYCLOOXYGENASE 2; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION; INFLAMMATION; MALE; NF-KAPPA B; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SMAD PROTEINS; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77951996610     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.03.008     Document Type: Article

References (27)

1. Finne P., Reunanen A., Stenman S., Groop P.H., Gronhagen-Riska C. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 2005, 294(14):1782-1787.
2. Navarro J.F., Mora-Fernandez C. The role of TNF-alpha in diabetic nephropathy: pathogenic and therapeutic implications. Cytokine Growth Factor Rev. 2006, 17(6):441-450.
3. Jafarnejad A., Bathaie S.Z., Nakhjavani M., Hassan M.Z. Investigation of the mechanisms involved in the high-dose and long-term acetyl salicylic acid therapy of type I diabetic rats. J. Pharmacol. Exp. Ther. 2008, 324(2):850-857.
4. Gross J.L., de Azevedo M.J., Silveiro S.P., Canani L.H., Caramori M.L., Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diab. Care 2005, 28(1):164-176.
5. Singh R., Singh A.K., Alavi N., Leehey D.J. Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J. Am. Soc. Nephrol. 2003, 14(4):873-880.
6. Chung O., Kuhl H., Stoll M., Unger T. Physiological and pharmacological implications of AT1 versus AT2 receptors. Kidney Int. Suppl. 1998, 67:S95-99.
7. Gawaz M., Langer H., May A.E. Platelets in inflammation and atherogenesis. J. Clin. Invest. 2005, 115(12):3378-3384.
8. Tu X., Chen X., Xie Y., Shi S., Wang J., Chen Y., Li J. Anti-inflammatory renoprotective effect of clopidogrel and irbesartan in chronic renal injury. J. Am. Soc. Nephrol. 2008, 19(1):77-83.
9. King G.L. The role of inflammatory cytokines in diabetes and its complications. J. Periodontol. 2008, 79(Suppl. 8):1527-1534.
10. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., Qi N., Wang J., Avery M.A., Kurtz T.W. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004, 43(5):993-1002.
11. Kurtz T.W., Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J. Hypertens. 2004, 22(12):2253-2261.
12. Fidaleo M., Berardi E., Sartori C. Differential modulation of PPARalpha and gamma target gene expression in the liver and kidney of rats treated with aspirin. Exp. Toxicol. Pathol. 2008, 59(6):391-397.
13. Isono M., Chen S., Hong S.W., Iglesias-de la Cruz M.C., Ziyadeh F.N. Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-beta-induced fibronectin in mesangial cells. Biochem. Biophys. Res. Commun. 2002, 296(5):1356-1365.
14. Tikoo K., Meena R.L., Kabra D.G., Gaikwad A.B. Change in post-translational modifications of histone H3, heat-shock protein-27 and MAP kinase p38 expression by curcumin in streptozotocin-induced type I diabetic nephropathy. Br. J. Pharmacol. 2008, 153(6):1225-1231.
15. Makino H., Tanaka I., Mukoyama M., Sugawara A., Mori K., Muro S., Suganami T., Yahata K., Ishibashi R., Ohuchida S., Maruyama T., Narumiya S., Nakao K. Prevention of diabetic nephropathy in rats by prostaglandin E receptor EP1-selective antagonist. J. Am. Soc. Nephrol. 2002, 13(7):1757-1765.
16. Navarro-Gonzalez J.F., Jarque A., Muros M., Mora C., Garcia J. Tumor necrosis factor-alpha as a therapeutic target for diabetic nephropathy. Cytokine Growth Factor Rev. 2009, 20(2):165-173.
17. Goncalves A.R., Fujihara C.K., Mattar A.L., Malheiros D.M., Noronha Ide L., de Nucci G., Zatz R. Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory. Am. J. Physiol. Renal Physiol. 2004, 286(5):F945-954.
18. Kuhad A., Chopra K. Attenuation of diabetic nephropathy by tocotrienol: involvement of NFkB signaling pathway. Life Sci. 2009, 84(9-10):296-301.
19. Nobles-James C., James E.A., Sowers J.R. Prevention of cardiovascular complications of diabetes mellitus by aspirin. Cardiovasc. Drug Rev. 2004, 22(3):215-226.
20. Papadakis K.A., Targan S.R. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000, 119(4):1148-1157.
21. DiPetrillo K., Coutermarsh B., Gesek F.A. Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am. J. Physiol. Renal Physiol. 2003, 284(1):F113-121.
22. Kast R.E. Aspirin, TNF-alpha, NFkB, and survival in multiple myeloma: the importance of measuring TNF-alpha. Inflammopharmacology 2006, 14(5-6):256-259.
23. Tian Q., Miyazaki R., Ichiki T., Imayama I., Inanaga K., Ohtsubo H., Yano K., Takeda K., Sunagawa K. Inhibition of tumor necrosis factor-alpha-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-gamma with nuclear factor kappaB and CCAAT/enhancer-binding protein-beta. Hypertension 2009, 53(5):798-804.
24. Khan K.N., Paulson S.K., Verburg K.M., Lefkowith J.B., Maziasz T.J. Pharmacology of cyclooxygenase-2 inhibition in the kidney. Kidney Int. 2002, 61(4):1210-1219.
25. Wang W., Koka V., Lan H.Y. Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology (Carlton) 2005, 10(1):48-56.
26. Furuse Y., Hashimoto N., Maekawa M., Toyama Y., Nakao A., Iwamoto I., Sakurai K., Suzuki Y., Yagui K., Yuasa S., Toshimori K., Saito Y. Activation of the Smad pathway in glomeruli from a spontaneously diabetic rat model, OLETF rats. Nephron Exp. Nephrol. 2004, 98(3):e100-108.
27. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979, 95:351-358.